Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

immunotherapy

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

Roche - Basel

Roche invests in diagnostics in China

Commits 450m Swiss francs to manufacturing facility

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

EU flag

EC: medicines to remain part of health directorate

Juncker U-turns on decision to move pharma oversight to enterprise and industry

- PMLiVE

Roche outlines $3bn expansion for its Basel site

Decade-long programme will see the Swiss pharma company boost its presence in its home city

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

- PMLiVE

Pressure put on Roche to cut Kadcyla’s UK price

30,000 people sign petition to help make the breast cancer drug available on the NHS

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

- PMLiVE

Roche appoints Philip Atkinson to new global role

He will lead the company's new scientific communications group

- PMLiVE

Breast cancer drug market set to double in 10 years

New entrants will join market leaders Roche, Novartis and AstraZeneca

- PMLiVE

EMA draws fire on new clinical reports policy

Has recently come under pressure from transparency groups

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links